7 completed, 2 recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Recruiting 2 |
Follow Osilodrostat: new trials by email Literature Review of Osilodrostat trials Research Report on Osilodrostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 15 | 2026-01-14 | 2026-02-11 |
| Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome LCI699 - Cushing Syndrome | Phase 2 | Recruiting | RECORDATI GROUP | 12 | 2021-04-28 | 2026-03-27 |
| Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 osilodrostat - Cushing's Syndrome | Phase 2 | Completed | RECORDATI GROUP | 127 | 2018-10-05 | 2024-12-18 |
| Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Osilodrostat - Cushing's Syndrome, Ectopic Corticotropin Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 9 | 2015-09-24 | 2020-05-06 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients LCI699 - Cushings Disease, Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2011-03-23 | 2021-01-22 |
| A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension LCI699-matching placebo, LCI699 - Hypertension | Phase 2 | Completed | Novartis | 63 | 2009-01-14 | 2021-06-02 |
| A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension LCI699, Eplerenone, LCI699-matching Placebo - Hypertension | Phase 2 | Completed | Novartis | 155 | 2008-12-22 | 2021-06-02 |
| A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension LCI699, Eplerenone, LCI699-matching Placebo - Essential Hypertension | Phase 2 | Completed | Novartis Pharmaceuticals | 628 | 2008-09-11 | 2021-07-06 |
| Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism LCI699 - Primary Hyperaldosteronism | Phase 2 | Completed | Novartis | 12 | 2008-06-01 | 2009-08-26 |
Cushing Syndrome (4) · Hypertension (3) · ACTH Syndrome, Ectopic (2) · Pituitary Diseases (2) · Acth-Independent Macronodular Adrenal Hyperplasia (1) · Adrenal Cortex Neoplasms (1) · Adrenal Hyperplasia, Congenital (1) · Adrenocortical Hyperfunction (1) · Essential Hypertension (1) · Hyperaldosteronism (1) · Hypokalemia (1) · Pituitary ACTH Hypersecretion (1)
Novartis (3) · Novartis Pharmaceuticals (3) · RECORDATI GROUP (2) · Mayo Clinic (1)
United States (7) · France (4) · Italy (3) · Japan (3) · Belgium (2) · Bulgaria (2) · Iceland (2) · Argentina (1) · Austria (1) · Brazil (1) · Canada (1) · China (1) · Costa Rica (1) · Germany (1) · India (1)
Irina Bancos, MD (1) · Recordati AG (1)
PMID 24107737, PMID 20837883, PMID 21986283, PMID 24423285, PMID 41052284
2008 (2), 2018 (1)